Carsten Maik Naumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carsten Maik Naumann has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Daniar Osmonov
Department of Urology, University Medical Center Schleswig-Holstein, Campus Lübeck, Germany
4 shared publications - Alexey Pryalukhin
Institute of Pathology, University Medical Centre Bonn, Bonn, Germany
3 shared publications Anabel Zwick
Institute of Virology, University of Saarland, Homburg, Germany
3 shared publications- Arndt Hartmann
Institute of Pathology University Hospital Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Erlangen Germany
3 shared publications Carol-Immanuel Geppert
Institute of Pathology, University Erlangen-Nuremberg, Erlangen, Germany
3 shared publications- Gilles Gasparoni
Department of Genetics/Epigenetics Universität Des Saarlandes Saarbrücken Germany
3 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Squamous penile cancer displays a rare human papillomavirus (HPV)–associated tumor entity. Investigations on the molecular pathogenesis of HPV-driven penile cancer are impaired by the rareness of clinical specimens and, in particular, are missing relevant cell culture models. Here, we identified in HPV-positive penile cancer cell lines that HPV16 oncoproteins control TP63 expression by modulating critical regulators, while integration into the TP63 open reading frame facilitates oncogene expression. The resulting feed-forward loop leads to elevated p63 levels that in turn enhance the release of the neutrophil-recruiting chemokine CXCL8. Remarkably, elevated CXCL8 amounts lead to the increased surface exposition of the Fc receptor of human IgA antibodies, FcαRI, on neutrophils and correlated with a higher susceptibility to antibody-dependent neutrophil-mediated cytotoxicity (ADCC) using an EGFR-specific IgA2 antibody. IHC staining of tissue microarrays proved that elevated expression of p63 together with neutrophil infiltration were significantly more frequent in HPV-positive penile cancer displaying a higher tumor grade. In summary, we identified a promising marker profile of patients with penile cancer at higher risk for worse prognosis. However, these patients may benefit from immunotherapeutic approaches efficiently engaging neutrophils for tumor cell killing.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
Squamous penile cancer displays a rare human papillomavirus (HPV)–associated tumor entity. Investigations on the molecular pathogenesis of HPV-driven penile cancer are impaired by the rareness of clinical specimens and, in particular, are missing relevant cell culture models. Here, we identified in HPV-positive penile cancer cell lines that HPV16 oncoproteins control TP63 expression by modulating critical regulators, while integration into the TP63 open reading frame facilitates oncogene expression. The resulting feed-forward loop leads to elevated p63 levels that in turn enhance the release of the neutrophil-recruiting chemokine CXCL8. Remarkably, elevated CXCL8 amounts lead to the increased surface exposition of the Fc receptor of human IgA antibodies, FcαRI, on neutrophils and correlated with a higher susceptibility to antibody-dependent neutrophil-mediated cytotoxicity (ADCC) using an EGFR-specific IgA2 antibody. IHC staining of tissue microarrays proved that elevated expression of p63 together with neutrophil infiltration were significantly more frequent in HPV-positive penile cancer displaying a higher tumor grade. In summary, we identified a promising marker profile of patients with penile cancer at higher risk for worse prognosis. However, these patients may benefit from immunotherapeutic approaches efficiently engaging neutrophils for tumor cell killing.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S157
Perioperative use of anticholinergic medication in patients undergoing surgery for male urinary stress incontinence
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S157
Perioperative use of anticholinergic medication in patients undergoing surgery for male urinary stress incontinence
- 1 January 2018
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 44 (4) , 303-310
Surgical site infections after radical prostatectomy: A comparative study between robot-assisted laparoscopic radical prostatectomy and retropubic radical prostatectomy
Objective: Surgical site infection (SSI) is defined as infection at or near surgical incisions within 30 days of an operative procedure and classified either incisional superficial and deep or organ/space. The aim of the study is to report and compare the incidence and management of SSIs after robot-assisted laparoscopic radical prostatectomy (RALP) and retropubic radical prostatectomy (RRP). Material and methods: Within the last 4 years, we identified 285 patients that underwent RRP, n=187 (66%) or RALP, n=98 (34%). We reviewed the frequency, types and way of management of SSI complications. Results: A significant difference was found between RALP and RRP (2/98, 2% vs. 27/187, 14.4%; p
- 1 January 2018
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 44 (4) , 303-310
Surgical site infections after radical prostatectomy: A comparative study between robot-assisted laparoscopic radical prostatectomy and retropubic radical prostatectomy
Objective: Surgical site infection (SSI) is defined as infection at or near surgical incisions within 30 days of an operative procedure and classified either incisional superficial and deep or organ/space. The aim of the study is to report and compare the incidence and management of SSIs after robot-assisted laparoscopic radical prostatectomy (RALP) and retropubic radical prostatectomy (RRP). Material and methods: Within the last 4 years, we identified 285 patients that underwent RRP, n=187 (66%) or RALP, n=98 (34%). We reviewed the frequency, types and way of management of SSI complications. Results: A significant difference was found between RALP and RRP (2/98, 2% vs. 27/187, 14.4%; p
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e269
269 Overall and cancer-specific survival in patients undergoing salvage extended pelvic lymph node dissection in recurrent prostate cancer
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e269
269 Overall and cancer-specific survival in patients undergoing salvage extended pelvic lymph node dissection in recurrent prostate cancer
- 24 June 2008
- Published by Springer Nature in International Urology and Nephrology
- Vol. 41 (1) , 13-17
Ewing’s sarcoma of the urogenital tract
This article reviews the current available information on Ewing’s sarcoma of the urogenital tract, focusing on the presentation, diagnosis, and therapeutic management of this uncommon entity. Because of the rapid local growth of these tumors, an immediate decision for treatment initiation is mandatory. The classical presentation depends mainly on the site of involvement of these tumors, involving a palpable mass, hematuria, and pain. No specific diagnostic imaging is available to date, and the only diagnostic method remains histological examination in combination with immunohistochemistry. Treatment involves primary surgical resection of all tumor tissues followed by adjuvant multi-agent chemotherapy. Overall survival is poor, although a 13-year survival has been reached in one case.
- 24 June 2008
- Published by Springer Nature in International Urology and Nephrology
- Vol. 41 (1) , 13-17
Ewing’s sarcoma of the urogenital tract
This article reviews the current available information on Ewing’s sarcoma of the urogenital tract, focusing on the presentation, diagnosis, and therapeutic management of this uncommon entity. Because of the rapid local growth of these tumors, an immediate decision for treatment initiation is mandatory. The classical presentation depends mainly on the site of involvement of these tumors, involving a palpable mass, hematuria, and pain. No specific diagnostic imaging is available to date, and the only diagnostic method remains histological examination in combination with immunohistochemistry. Treatment involves primary surgical resection of all tumor tissues followed by adjuvant multi-agent chemotherapy. Overall survival is poor, although a 13-year survival has been reached in one case.